Lotte Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma

Why It Matters

The expanded deal speeds Ottimo’s dual‑target antibody toward market, highlighting how integrated CDMOs can accelerate complex biologics development and give biotech firms a competitive edge.

Key Takeaways

• Lotte Biologics adds OTP‑01 manufacturing to existing partnership
• Dual‑paratopic PD‑1/VEGFR2 antibody targets cancer immune evasion
• Syracuse and Songdo campuses enable seamless development to commercial scale
• Expanded deal accelerates Ottimo’s Phase 1/2a trial timeline

Pulse Analysis

The contract manufacturing organization (CDMO) market is entering a phase of consolidation around integrated, global players that can shepherd biologics from early‑stage development to commercial supply. Lotte Biologics, a pure‑play CDMO, differentiates itself with dual campuses in Syracuse, New York, and Songdo, South Korea, offering clients consistent quality, flexible capacity, and regulatory alignment across continents. This geographic breadth reduces hand‑off risk and shortens timelines, a critical advantage for biotech firms racing to bring novel therapies to patients.

Dual‑paratopic antibodies, which bind two distinct epitopes on separate targets, represent a cutting‑edge approach to overcoming tumor immune evasion. OTP‑01, Ottimo Pharma’s PD‑1/VEGFR2 bispecific construct, aims to simultaneously block the PD‑1 checkpoint and inhibit VEGF‑driven angiogenesis, a strategy that could improve response rates in solid tumors. By expanding its manufacturing scope, Lotte will handle not only cell‑culture production but also commercial‑scale process development, ensuring the molecule meets stringent purity and potency standards required for late‑stage trials and eventual market launch.

For Ottimo Pharma, the expanded partnership translates into faster initiation of its Phase 1/2a study and a clearer path to regulatory filing. Leveraging Lotte’s expertise reduces the need for in‑house scale‑up infrastructure, allowing Ottimo to allocate resources toward clinical design and data generation. This collaboration mirrors a broader industry trend where biotech innovators partner with specialized CDMOs to de‑risk development, accelerate timelines, and attract investment. As dual‑target biologics gain traction, the Lotte‑Ottimo alliance positions both companies to capture emerging market share in oncology therapeutics.